RFG Advisory LLC Grows Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

RFG Advisory LLC raised its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 305.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 48,810 shares of the company's stock after buying an additional 36,786 shares during the period. RFG Advisory LLC's holdings in Novo Nordisk A/S were worth $3,389,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of NVO. Center for Financial Planning Inc. boosted its position in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after acquiring an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL lifted its stake in Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Park Square Financial Group LLC acquired a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $29,000. Transce3nd LLC purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $33,000. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $39,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVO has been the subject of several analyst reports. Wall Street Zen upgraded Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Finally, Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $128.00.

Novo Nordisk A/S Stock Up 0.7%

Shares of NYSE NVO traded up $0.53 during midday trading on Thursday, hitting $72.57. The company's stock had a trading volume of 5,088,580 shares, compared to its average volume of 6,858,483. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The firm has a market capitalization of $325.64 billion, a price-to-earnings ratio of 22.06, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. The business's fifty day simple moving average is $65.67 and its two-hundred day simple moving average is $81.09. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The company had revenue of $11.87 billion during the quarter. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.